SC-43

• CAT Number: I010728
• CAS Number: 1400989-25-4
• Molecular Formula: C₂₁H₁₃ClF₃N₃O₂
• Molecular Weight: 431.8
• Purity: ≥95%

SC-43(CAT: I010728), a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. It inhibits STAT3 phosphorylation, induces cell apoptosis, and exhibits anti-proliferative effects in cholangiocarcinoma (CCA) cell lines. SC-43 activates SHP-1 by binding to its N-SH2 domain and relieving autoinhibition, resulting in downstream downregulation of cyclin B1 and Cdc2. In animal studies, SC-43 inhibits xenograft tumor growth, reduces p-STAT3 levels, and elevates SHP-1 activity. These findings suggest that SC-43 has potential as an anti-fibrotic and anticancer agent, particularly in CCA. Further research is needed to explore its therapeutic applications.

Reference

[1]. Ming-Hung Hu, et al. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017 May 10;8(39):65077-65089.[2]. Tung-Hung Su, et al. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep. 2017 May 11;7(1):1728.